医疗设备公司Neuronetics宣布任命史蒂文·普凡斯蒂尔（Steven Pfanstiel）担任首席财务官，接替今年早些时候表明退休意向的史蒂夫·弗隆（Steve Furlong）。弗隆将留任公司高级顾问直至明年三月，协助确保管理权平稳过渡。
现年52岁的普凡斯蒂尔此前在Marinus Pharmaceuticals担任首席财务及运营官。Neuronetics特别指出，他在该公司旗舰产品Ztalmy的商业化上市过程中发挥了关键作用。在加入Marinus之前，这位财务专家曾在Lifescan、Optinose等多家医疗健康企业担任高级财务管理职务，职业生涯早期更在强生集团担任过高级财务职位。
根据聘任条款，普凡斯蒂尔将获得48万美元的基本年薪，同时可享有目标为基本工资50%的年度现金奖金及股票期权激励。此次人事任命公布之际，该公司重申了第二季度及全年业绩指引：预计最近季度营收将达3600万至3800万美元区间，全年营收则维持在1.49亿至1.55亿美元预测范围。
值得注意的是，Neuronetics强调公司运营状况良好，仍有望在2025年第三季度实现正向现金流，这标志着该企业向持续盈利目标迈出了关键性一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.